Fusion proteins present in leukemic cells frequently contain a new amino acid at the fusion point. We tested whether a peptide (BCR1/25) encompassing the fusion region of the hybrid molecule pml/RAR alpha, which is selectively expressed by acute promyelocytic leukemia (APL) cells, can be recognized by human T lymphocytes in vitro. CD4+ lymphocytes, at both polyclonal and clonal level, recognized peptide BCR1/25 in an HLA-DR--restricted fashion on presentation by autologous antigen-presenting cell (APC) or by APC expressing the HLA-DR11 restricting molecule. Control peptides corresponding to the normal pml and RAR alpha proteins were not recognized. One clone (DEG5) also exerted a high and specific cytotoxicity against autologous cells pulsed with BCR1/25. The autologous DE LCL containing a transduced pml/RAR alpha fusion gene and expressing a bcr1 type of the pml/RAR alpha hybrid protein induced the proliferation of DE anti-BCR1/25 T cell clones. It is concluded that the bcr1 type-pml/RAR alpha fusion protein of APL contains an antigenic site, absent from the normal parent molecules and recognized by human CD4+ lymphocytes.
|Titolo:||Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells|
PELICCI, PIER GIUSEPPE (Penultimo)
|Parole Chiave:||Carrier Proteins; Humans; Recombinant Fusion Proteins; Amino Acid Sequence; CD4-Positive T-Lymphocytes; Tumor Suppressor Proteins; Lymphocyte Activation; Cytotoxicity, Immunologic; Receptors, Retinoic Acid; Neoplasm Proteins; Transcription Factors; Nuclear Proteins; Cells, Cultured; HLA-DR Antigens; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Oncogene Proteins, Fusion|
|Settore Scientifico Disciplinare:||Settore MED/04 - Patologia Generale|
|Data di pubblicazione:||1-mar-1993|
|Appare nelle tipologie:||01 - Articolo su periodico|